Executive Vice President and Chief Medical Officer

Pierre Dodion joined Innate Pharma in September 2014. He has 25 years of experience in Medical affairs in the pharmaceutical industry having worked at Pfizer (2006-2008), Novartis (2002-2006) and Aventis (1996-2002). He contributed to the development, approval and launch of several drugs, including sunitinib (Sutent®, kidney cancer and GIST) and letrozole (Femara®, breast cancer).

In 2007, Pierre Dodion joined ARIAD Pharmaceuticals (Nasdaq: ARIA), first as SVP and Chief Medical Officer, then as SVP Corporate Development and Operations. He played a major role in the expansion of ARIAD, notably in Europe. He contributed to two development programs in oncology: ridaforolimus (licensed to Merck) and ponatinib (marketed by ARIAD Pharmaceuticals as Iclusig®).

Pierre Dodion is a medical doctor, with a specialization degree in Oncology from the Free University of Brussels, Belgium and a MBA degree from the Saint Joseph University of Philadelphia, PA.